Daniel Roeser > Goodwin > New York, United States > Lawyer Profile
Goodwin Offices
THE NEW YORK TIMES BUILDING
620 EIGHTH AVENUE
NEW YORK NY 10018
NEW YORK
United States
- Firm Profile
- Go to...
Daniel Roeser
Position
Partner
Career
Dan Roeser is a partner in Goodwin’s Securities Litigation & White Collar Defense group and its Digital Currency & Blockchain Technology practice. Mr. Roeser represents companies and institutions, underwriters, and individuals in securities actions, shareholder derivative actions, and criminal and regulatory proceedings. His clients span a wide range of industries, including financial services, life sciences, and technology:
- Companies and Institutions: Mr. Roeser has represented an array of domestic and international companies and institutions, including Cognizant Technology Solutions Corporation; Countrywide Financial Corporation, the Tezos Foundation, and Nomura Securities International, Inc.
- Underwriters: Mr. Roeser has represented syndicates of investment banks that underwrote primary and secondary public offerings of issuers across several industries, including financial services, money transfer and payment services, and life sciences.
- Individuals: Mr. Roeser has represented a series of C-suite officers and other individuals, including the former CEO of Wells Fargo; the former CEO of Petrobras; the Chairman and CEO of Caesars Entertainment Corporation; and the CFO of Pfizer, Inc.
- Criminal and Regulatory Proceedings: Mr. Roeser has represented individuals and institutions in criminal insider trading cases and investigations by the United States Attorney’s Office, the Securities and Exchange Commission, and the Chicago Mercantile Exchange.
Mr. Roeser’s cases involve some of the most high-profile matters of their kind, such as the Wells Fargo, Petrobras and Caesars litigations, as well as legal issues that are at the leading edge of securities law, such as digital currency + blockchain technology; high frequency, algorithmic trading; and spoofing.
Education
JD, Harvard Law School (cum laude) 2002 / AB, Harvard College (magna cum laude) 1997
Lawyer Rankings
United States > Dispute resolution > Securities litigation: defense
Goodwin is known as one of the leading life sciences firms in the US, as well as a prominent player in matters concerning technology companies and REITs. The firm is handling a growing volume of class actions, derivative cases and SEC investigations, particularly for tech companies. Clients note that the firm’s ‘judgement, subject knowledge and guidance is outstanding’ and are ‘impressed with their technical insights combined with practical experience’. Deborah Birnbach leads the practice from Boston, where Adam Slutsky and Caroline Bullerjahn are among the standout partners. Birnback and Bullerjahn obtained full dismissal of a securities class action against biopharma company Alkermes plc, which was accused of making misstatements and omissions regarding the development program for a clinical stage drug for a major depressive disorder. Daniel Roeser in New York is representing underwriting syndicates in a putative securities class action filed in Florida federal court against Axogen. Key partner Brian Pastuszenski retired, but Jonathan Shapiro in San Francisco from Baker Botts L.L.P. (who is ‘a highly capable attorney with a dynamic and empathetic personality’) reinforces the firm’s stronghold in its key sectors. Jonathan Hecht in Washington DC joined from the SEC and is ‘a transformative presence’ in enforcement matters.
Lawyer Rankings
Top Tier Firm Rankings
- Finance > Financial services regulation
- Industry focus > Cannabis
- Intellectual property > Patents: licensing
- Real estate > Real estate investment trusts (REITs)
- Media, technology and telecoms > Technology transactions
- M&A/corporate and commercial > Venture capital and emerging companies
Firm Rankings
- Finance > Capital markets: equity offerings
- Industry focus > Education
- Labor and employment > ERISA litigation
- Finance > Fintech
- Healthcare > Life sciences
- Dispute resolution > M&A litigation: defense
- M&A/corporate and commercial > M&A: middle-market ($500m-999m)
- Investment fund formation and management > Mutual/registered/exchange-traded funds
- Dispute resolution > Securities litigation: defense
- Finance > Capital markets: debt offerings
- International Trade > CFIUS
- M&A/corporate and commercial > Corporate governance
- Media, technology and telecoms > Cyber law (including data privacy and data protection)
- Dispute resolution > E-discovery
- Labor and employment > Employee benefits, executive compensation and retirement plans: transactional
- Dispute resolution > Financial services litigation
- Antitrust > Merger control
- Intellectual property > Patents: litigation (full coverage)
- Investment fund formation and management > Private equity funds (including venture capital)
- Dispute resolution > Product liability, mass tort and class action - defense: consumer products (including tobacco)
- Real estate > Real estate
- M&A/corporate and commercial > Shareholder activism
- Intellectual property > Trade secrets (litigation and non-contentious matters)
- Tax > US taxes: non-contentious
- Labor and employment > Workplace and employment counseling
- Labor and employment > Employee benefits, executive compensation and retirement plans: design
- Dispute resolution > Leading trial lawyers
- M&A/corporate and commercial > Private equity buyouts: large deals ($500m+)
- Healthcare > Service providers
- International Trade > Customs, export controls and economic sanctions
- Dispute resolution > Leading trial lawyers
- Finance > Restructuring (including bankruptcy): corporate
- Dispute resolution > Appellate: courts of appeals / Appellate: supreme courts (states and federal)
- Finance > Commercial lending
- Dispute resolution > Corporate investigations and white-collar criminal defense
- Intellectual property > Patents: prosecution (including re-examination and post-grant proceedings)